News
Zacks.com on MSN52m
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback